The article presents a commentary on the study "Value of Routine Monitoring of Bone Mineral Density (BMD) After Starting Biphosphonate Treatment: Secondary Analysis of Trial Data." It attempts to put the need for BMD monitoring in an appropriate clinical context and focuses on the renewed concern on the utility of BMD testing to monitor therapy relative to the concept of "regression to the mean." The concept, pertinent at population level, was found to be misleading and irrelevant to the clinical management of individual patients.